129 related articles for article (PubMed ID: 8977754)
1. Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men.
Romeo JH; Dombrowski R; Kwak YS; Fuehrer S; Aron DC
Clin Endocrinol (Oxf); 1996 Nov; 45(5):571-5. PubMed ID: 8977754
[TBL] [Abstract][Full Text] [Related]
2. The prevalence of hyperprolactinaemia and association with markers of autoimmune thyroid disease in survivors of the Whickham Survey cohort.
Vanderpump MP; French JM; Appleton D; Tunbridge WM; Kendall-Taylor P
Clin Endocrinol (Oxf); 1998 Jan; 48(1):39-44. PubMed ID: 9509066
[TBL] [Abstract][Full Text] [Related]
3. Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinaemia.
Larrea F; Sandoval JL; Salinas E; Franco-Rodriguez VA; Méndez I; Ulloa-Aguirre A
Clin Endocrinol (Oxf); 1995 Nov; 43(5):591-600. PubMed ID: 8548944
[TBL] [Abstract][Full Text] [Related]
4. Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma.
Dombrowski RC; Romeo JH; Aron DC
Ann Pharmacother; 1995 Oct; 29(10):999-1001. PubMed ID: 8845563
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of hyperprolactinaemia in female premenopausal blood donors.
Alpañés M; Sanchón R; Martínez-García MÁ; Martínez-Bermejo E; Escobar-Morreale HF
Clin Endocrinol (Oxf); 2013 Oct; 79(4):545-9. PubMed ID: 23445257
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia.
Kelley SR; Kamal TJ; Molitch ME
Am J Physiol; 1996 Jan; 270(1 Pt 1):E96-100. PubMed ID: 8772480
[TBL] [Abstract][Full Text] [Related]
7. Calcium and prolactin secretion in humans: effects of the channel blocker, verapamil, in the spontaneous and drug-induced hyperprolactinemia.
Knoepfelmacher M; Villares SM; Nicolau W; Germek OO; Lerário AC; Wajchenberg BL; Liberman B
Horm Metab Res; 1994 Oct; 26(10):481-5. PubMed ID: 7851873
[TBL] [Abstract][Full Text] [Related]
8. Hyperprolactinaemia in hypothyroidism: clinical significance and impact of TSH normalization.
Raber W; Gessl A; Nowotny P; Vierhapper H
Clin Endocrinol (Oxf); 2003 Feb; 58(2):185-91. PubMed ID: 12580934
[TBL] [Abstract][Full Text] [Related]
9. Pituitary macroadenomas associated with hyperprolactinaemia: immunocytochemical and in-situ hybridization studies.
McNicol AM; Walker E; Farquharson MA; Teasdale GM
Clin Endocrinol (Oxf); 1991 Sep; 35(3):239-44. PubMed ID: 1742881
[TBL] [Abstract][Full Text] [Related]
10. Testosterone replacement-induced hyperprolactinaemia: case report and review of the literature.
Sodi R; Fikri R; Diver M; Ranganath L; Vora J
Ann Clin Biochem; 2005 Mar; 42(Pt 2):153-9. PubMed ID: 15829128
[TBL] [Abstract][Full Text] [Related]
11. [Macroprolactin in subjects with hyperprolactinaemia: clinical observations and relations between free PRL and PRL complexed with IgG].
Jeske W; Zgliczyński W; Gorzelak K
Endokrynol Pol; 2005; 56(5):779-84. PubMed ID: 16817144
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of endocrine tests. A: the TRH test in patients with hyperprolactinaemia.
Le Moli R; Endert E; Fliers E; Prummel MF; Wiersinga WM
Neth J Med; 2003 Feb; 61(2):44-8. PubMed ID: 12735420
[TBL] [Abstract][Full Text] [Related]
13. Psychological distress in patients with hyperprolactinaemia.
Reavley A; Fisher AD; Owen D; Creed FH; Davis JR
Clin Endocrinol (Oxf); 1997 Sep; 47(3):343-8. PubMed ID: 9373457
[TBL] [Abstract][Full Text] [Related]
14. An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinaemia.
Sawers HA; Robb OJ; Walmsley D; Strachan FM; Shaw J; Bevan JS
Clin Endocrinol (Oxf); 1997 Mar; 46(3):321-6. PubMed ID: 9156042
[TBL] [Abstract][Full Text] [Related]
15. Distinctive features of prolactin secretion in acromegalic patients with hyperprolactinaemia.
Serri O; Robert F; Comtois R; Jilwan N; Beauregard H; Hardy J; Somma M
Clin Endocrinol (Oxf); 1987 Oct; 27(4):429-36. PubMed ID: 3124991
[TBL] [Abstract][Full Text] [Related]
16. Divergence between growth hormone responses to insulin-induced hypoglycaemia and growth hormone-releasing hormone in patients with non-functioning pituitary macroadenomas and hyperprolactinaemia.
Beentjes JA; Tjeerdsma G; Sluiter WJ; Dullaart RP
Clin Endocrinol (Oxf); 1996 Oct; 45(4):391-8. PubMed ID: 8959076
[TBL] [Abstract][Full Text] [Related]
17. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy.
Colao A; Di Sarno A; Guerra E; Pivonello R; Cappabianca P; Caranci F; Elefante A; Cavallo LM; Briganti F; Cirillo S; Lombardi G
Clin Endocrinol (Oxf); 2007 Sep; 67(3):426-33. PubMed ID: 17573902
[TBL] [Abstract][Full Text] [Related]
18. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.
Karavitaki N; Thanabalasingham G; Shore HC; Trifanescu R; Ansorge O; Meston N; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2006 Oct; 65(4):524-9. PubMed ID: 16984247
[TBL] [Abstract][Full Text] [Related]
19. Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction.
Corona G; Rastrelli G; Boddi V; Monami M; Melani C; Balzi D; Sforza A; Forti G; Mannucci E; Maggi M
Int J Androl; 2011 Jun; 34(3):217-24. PubMed ID: 20522124
[TBL] [Abstract][Full Text] [Related]
20. Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up.
Berinder K; Stackenäs I; Akre O; Hirschberg AL; Hulting AL
Clin Endocrinol (Oxf); 2005 Oct; 63(4):450-5. PubMed ID: 16181238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
